Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Shares Sold by Woodline Partners LP

Woodline Partners LP trimmed its stake in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) by 64.7% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 567,060 shares of the company's stock after selling 1,037,471 shares during the period. Woodline Partners LP owned about 0.18% of Amneal Pharmaceuticals worth $4,491,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of AMRX. Vanguard Group Inc. boosted its position in Amneal Pharmaceuticals by 1.5% during the fourth quarter. Vanguard Group Inc. now owns 14,841,969 shares of the company's stock valued at $117,548,000 after acquiring an additional 218,025 shares during the last quarter. Dimensional Fund Advisors LP raised its stake in Amneal Pharmaceuticals by 5.9% during the 4th quarter. Dimensional Fund Advisors LP now owns 4,991,702 shares of the company's stock worth $39,531,000 after buying an additional 278,653 shares during the period. Geode Capital Management LLC raised its stake in Amneal Pharmaceuticals by 0.7% during the 4th quarter. Geode Capital Management LLC now owns 3,813,207 shares of the company's stock worth $30,207,000 after buying an additional 26,536 shares during the period. Nantahala Capital Management LLC raised its stake in Amneal Pharmaceuticals by 37.3% during the 4th quarter. Nantahala Capital Management LLC now owns 3,665,529 shares of the company's stock worth $29,031,000 after buying an additional 995,586 shares during the period. Finally, BlackBarn Capital Partners LP raised its stake in Amneal Pharmaceuticals by 18.2% during the 4th quarter. BlackBarn Capital Partners LP now owns 2,850,000 shares of the company's stock worth $22,572,000 after buying an additional 438,388 shares during the period. 31.82% of the stock is currently owned by institutional investors and hedge funds.

Amneal Pharmaceuticals Trading Up 0.4%

Shares of AMRX stock traded up $0.03 during trading hours on Thursday, reaching $7.24. The stock had a trading volume of 288,793 shares, compared to its average volume of 1,441,938. The firm has a market capitalization of $2.27 billion, a PE ratio of -10.64 and a beta of 1.17. Amneal Pharmaceuticals, Inc. has a 12 month low of $6.29 and a 12 month high of $9.48. The stock's fifty day simple moving average is $7.53 and its 200 day simple moving average is $8.03.

Amneal Pharmaceuticals (NASDAQ:AMRX - Get Free Report) last posted its quarterly earnings results on Friday, May 2nd. The company reported $0.19 EPS for the quarter, topping the consensus estimate of $0.14 by $0.05. The firm had revenue of $695.42 million for the quarter, compared to the consensus estimate of $714.78 million. Amneal Pharmaceuticals had a negative net margin of 6.88% and a negative return on equity of 346.26%. As a group, equities research analysts anticipate that Amneal Pharmaceuticals, Inc. will post 0.53 EPS for the current fiscal year.

Analysts Set New Price Targets

Several analysts have recently commented on AMRX shares. JPMorgan Chase & Co. upgraded shares of Amneal Pharmaceuticals from a "neutral" rating to an "overweight" rating and increased their target price for the company from $9.00 to $12.00 in a report on Monday, February 24th. Barclays increased their target price on shares of Amneal Pharmaceuticals from $10.00 to $11.00 and gave the stock an "overweight" rating in a research report on Monday, March 3rd. Finally, Wall Street Zen lowered shares of Amneal Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research report on Tuesday, May 13th. Five analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has a consensus rating of "Buy" and an average price target of $11.50.

Insiders Place Their Bets

In other Amneal Pharmaceuticals news, Director Gautam Patel sold 80,000 shares of the stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $8.90, for a total value of $712,000.00. Following the sale, the director now owns 1,808,886 shares in the company, valued at $16,099,085.40. This trade represents a 4.24% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, major shareholder Tushar Bhikhubhai Patel sold 5,000,000 shares of the firm's stock in a transaction dated Friday, March 14th. The stock was sold at an average price of $8.35, for a total value of $41,750,000.00. Following the completion of the sale, the insider now directly owns 48,578,209 shares of the company's stock, valued at approximately $405,628,045.15. This represents a 9.33% decrease in their position. The disclosure for this sale can be found here. 17.45% of the stock is owned by insiders.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.